Amgen Inc logo

Amgen Inc

AMGN
Healthcare|Drug Manufacturers - General|USA
$342.57
-5.37 (-1.54%)
DCF (FCF)
$219.78
Earnings Power
$83.10

Upcoming Data Readouts (45)

May 2026
Est. completion
P1Advanced Solid Tumors
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT06131398n=77
May 2026
Est. completion
P1P2Advanced MTAP-null Solid Tumors
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
NCT05094336n=329
Jun 2026
Est. completion
P1P2Non Small Cell Lung Cancer
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810n=153
Jun 2026
Est. completion
P3Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356n=750
Jul 2026
Est. completion
P3Eosinophilic Esophagitis
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227n=368
Aug 2026
Est. completion
P3Sjogren's Syndrome
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124n=651
Oct 2026
Est. completion
P1Prostate Cancer
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
NCT06555796n=50
Dec 2026
Est. completion
P2Relapsed/Refractory Small Cell Lung Cancer
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016n=222
Dec 2026
Est. completion
NACrohn Disease (CD)
TIDHI Mental Health in IBD Patients Study
NCT07013578n=100
Jan 2027
Est. completion
P1Prostate Cancer
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
NCT06613100n=40
Feb 2027
Est. completion
P1P2Thyroid Eye Disease
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
NCT06401044n=88
Mar 2027
Est. completion
P2Premenopausal Idiopathic Osteoporosis
Romosozumab/Denosumab Study for Premenopausal IOP
NCT04800367n=30
May 2027
Est. completion
P4Glucocorticoid-induced Osteoporosis
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
NCT06588153n=100
Jun 2027
Est. completion
P1Asthma
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371n=124
Jun 2027
Est. completion
P3Atopic Dermatitis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877n=2,621
Sep 2027
Est. completion
P2Cancer
The Drug Rediscovery Protocol (DRUP Trial)
NCT02925234n=1,550
Sep 2027
Est. completion
P3Obstructive Sleep Apnea
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765n=250
Jan 2028
Est. completion
P1Brain Tumor
A Study of Sotorasib in People With Brain Tumors
NCT06807619n=16
Jan 2028
Est. completion
P2Systemic Lupus Erythematosus
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798n=220
Mar 2028
Est. completion
P1Extensive Stage Small Cell Lung Cancer
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
NCT07037758n=380

Awaiting Results (19)

Trials past primary completion date but still active — data readout may be imminent.

May 2026
P3
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT03937154
Mar 2026
P2
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
NCT06312020
Mar 2026
P2
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NCT04329325
Jan 2026
P2
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113
Dec 2025
P1
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
NCT02332850
Nov 2025
P1P2
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
NCT05322577
Nov 2025
P3
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
NCT05565560
Nov 2025
P3
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
NCT03836040
Oct 2025
P3
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
NCT05111626
Jul 2025
P3
Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)
NCT04483739

Recent Press Releases